Towards Healthcare
Antibody Therapy Market Soars USD 314.64 Billion in 2025 at 13.08% CAGR

Antibody Therapy Market 2025 is Accelerated by AI-Enhanced Discovery and Trials

Based on market forecasts, the global antibody therapy market, projected at USD 278.25 billion in 2024, is expected to reach USD 951.24 billion by 2034, growing at a CAGR of 13.08% over the forecast period. The antibody therapy market is expanding due to rising chronic diseases as well as growing advances in antibody discovery. North America led the market due to the presence of the advanced healthcare sector.

Category: Therapeutic Area Insight Code: 5850 Format: PDF / PPT / Excel

Antibody Therapy Market Size, Recent Developments and Key Players

The global antibody therapy market size is calculated at US$ 278.25 in 2024, grew to US$ 314.64 billion in 2025, and is projected to reach around US$ 951.24 billion by 2034. The market is expanding at a CAGR of 13.08% between 2025 and 2034.

The use of antibody therapies is increasing in the treatment of various diseases. The growing research and development to identify, design, and optimize are also enhancing their advancements, clinical trials, and launches. Additionally, new platforms are being developed with the use of AI to improve the antibody and its target discovery. This, in turn, is leading to new collaboration among the industries and institutes. Hence, their acceptance rate in various regions is increasing. Thus, all these factors are promoting the market growth.

Animal Biotechnology Market Size 2024 - 2034

Key Takeaways

  • Antibody therapy sector is pushing the market to USD 278.25 billion in 2024.
  • Long-term projections show USD 951.24 billion valuation by 2034.
  • Growth is expected at a steady CAGR of 13.08% in between 2025 to 2034.
  • North America held a 45% share in the global antibody therapy market in 2024.
  • Asia Pacific is expected to be the fastest-growing during the forecast period.
  • By antibody type, the monoclonal antibodies (mAbs) segment held a 64% share in the market in 2024.
  • By antibody type, the bispecific antibodies segment is expected to be the fastest growing at a notable CAGR during the forecast period.
  • By therapy area type, the oncology segment held a 48% share in the market in 2024.
  • By therapy area type, the neurology segment is expected to be the fastest growing during the forecast period.
  • By mechanism of action type, the targeted cell killing segment held a 40% share in the market in 2024.
  • By mechanism of action type, the immune modulation segment is expected to be the fastest growing during the forecast period.
  • By route of administration type, the intravenous (IV) segment held a 70% share in the market in 2024.
  • By route of administration type, the subcutaneous (SC) segment is expected to be the fastest growing during the forecast period.
  • By end user, the hospitals & clinics segment dominated the global antibody therapy market in 2024.
  • By end user, the contract research & manufacturing organizations (CROs/CMOs) segment is expected to be the fastest growing during the forecast period.

Key Indicators and Highlights

Metric Details
Market Size in 2025 USD 314.64 Billion
Projected Market Size in 2034 USD 951.24 Billion
CAGR (2025 - 2034) 13.08%
Leading Region North America share by 45%
Market Segmentation By Type of Antibody, By Therapy Area, By Mechanism of Action, By Route of Administration, By End-User, By Region
Top Key Players Takeda Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Merck & Co, Inc., Regeneron Pharmaceuticals, Merck & Co, IncSeagen, Seagen, Johnson & Johnson, F. Hoffmann-La Roche Ltd.

Market Overview

The antibody therapy market encompasses the development, production, and application of monoclonal antibodies (mAbs) and other antibody formats used to treat a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. These therapies target specific antigens to neutralize disease mechanisms, offering precision treatment with fewer side effects than traditional drugs. Key modalities include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and immune checkpoint inhibitors. At the same time, the new antibody targets and antibody discovery advancements can enhance the design and development of antibody therapies.

  • In July 2025, a collaboration between Invivyd, Inc. and Spike Protein Elimination and Recovery) The SPEAR Study Group was announced. The clinical trials for the evaluation of anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in Long Covid or Post-Vaccination Syndrome (PVS) will be guided and structured by the SPEAR Study Group. (Source - PharmzaBiz)
  • In June 2025, the Exigent and ONCare Alliance T-Cell Mediated Therapy Program was launched by the collaboration between ONCare Alliance and Exigent Research, which is a dynamic and revolutionary bispecific antibody program. This program will help to transform cancer care. (Source - Access newswire)

AI Integration in the Antibody Therapy Market

AI plays a crucial role in the design and discovery of antibodies for antibody therapies. It also helps in the optimization and development of the therapies. Moreover, AI and machine learning (ML) can be used in the computational prediction of antibody structure and antigen interface or interaction. Additionally, various models are being developed to predict the antibody non-specific binding and affinity with the use of antibody datasets.  Thus, the use of AI for the design, development, and optimization of potent antibody therapies is increasing.

Market Dynamics

Driver

Increasing Chronic Diseases

The growing incidence of chronic diseases such as cancer, asthma, diabetes, etc., is increasing the demand for the use of antibody therapies. The antibody therapies provide target-specific action, minimizing the side effects associated with them. They are also being used in the treatment of recurring diseases or as an alternative for resistant treatment options. Thus, they reduce the chances of disease relapses and surgeries in many cases, which in turn, enhances the patient outcomes. Thus, all these factors are driving the antibody therapy market growth.

Estimated Number of Cancer Patients in U.S.

The graph represents a comparison between the cancer patients in the U.S. in the year of 2025 and 2035. It indicates that there will be a rise in cases of cancer. Hence, it increases the demand for the use of antibody therapies for its effective management. Thus, this in turn will ultimately promote the market growth.

Restraint

Complex Manufacturing

The manufacturing of antibody therapies requires advanced equipment and consists of a multistep procedure. Variation in these steps affects its safety, efficacy, and potency. Moreover, there is a high chance of contamination, increasing the need for quality control procedures. Additionally, the regulatory hurdles also delay their manufacturing.

Opportunity

Increasing Advances in Antibody Discovery

There is a rise in the discovery of antibodies to develop effective and safe antibody therapies for the management of various diseases. At the same time, various platforms are being developed to accelerate their discoveries, enhance their efficacy, and minimize their toxicity. These antibodies are further used for the development of bispecific antibodies, antibody drug conjugates, etc., which are being used in the treatment of various infectious or rare diseases. Thus, all these developments are promoting the antibody therapy market growth.

For instance,

  • In July 2025, a new site of Hummingbird Bioscience at Singapore Science Park was launched, where, along with Callio Therapeutics two-pronged strategy to reshape cancer treatment is being developed. They are focusing on the development of multi-payload antibody-drug conjugates (ADCs) and tailor-made antibody discovery with the Rational Antibody Discovery (RAD) platform.

Segmental Insights

Which Antibody Type Segment Held the Dominating Share of the Antibody Therapy Market in 2024? 

By antibody type, the monoclonal antibodies (mAbs) segment held a dominating share of ~64% in the market in 2024. The mAbs showed target-specific action, which in turn increased their use in various diseases. Thus, various next-generation mAbs were used as treatment options. This contributed to the market growth.

By antibody type, the bispecific antibodies segment is expected to show the highest growth at a notable CAGR during the upcoming years. The bispecific antibodies are being used in the treatment of cancer and autoimmune diseases due to their dual targeting mechanism. Moreover, new candidates are also being developed and evaluated.

Why Oncology Segment Dominated the Antibody Therapy Market?

By therapy area type, the oncology segment led the market with ~48% in 2024. The growth in the incidence of cancer has increased the use of antibody therapies for its treatment. Moreover, their targeted action and personalized therapies enhanced their use.

By therapy area type, the neurology segment is expected to show the fastest growth rate during the predicted time. The increasing neurological diseases is increasing the use as well as development of various antibody therapies. This, in turn, is increasing the clinical trials and is supported by the government investments.

How Targeted Cell Killing Segment Dominated the Antibody Therapy Market in 2024?

By mechanism of action type, the targeted cell killing segment held the largest share of ~40% in the market in 2024. The targeted cell killing helped in reducing the cytotoxicity and other side effects. Hence, they were used in cancer treatment. Thus, this enhanced the market growth.

By mechanism of action type, the immune modulation segment is expected to show the highest growth during the forthcoming years. The immune modulation helps in stimulating or enhancing the immune system's responses against diseases. Hence, its use in autoimmune diseases is increasing.

What Made Intravenous (IV) the Dominant Segment in the Antibody Therapy Market in 2024?

By route of administration type, the intravenous (IV) segment led the market with ~70% in 2024. The intravenous route of administration showed a rapid onset of action along with enhanced bioavailability of the antibodies. Thus, this route was the preferred option for various large-sized antibodies.

By route of administration type, the subcutaneous (SC) segment is expected to show the fastest growth rate during the upcoming years. The patients are now shifting to the use of the subcutaneous route as it provides convenience to them. Moreover, the self-administration through this route is also increasing, which enhances the patient's adherence to the treatment.

Why Did the Hospitals & Clinics Segment Dominate in the Antibody Therapy Market in 2024?

By end user, the hospitals & clinics segment held the largest share of the market in 2024. A large volume of patients with different diseases were treated in the hospitals & clinics by using antibody therapies. Moreover, the presence of skilled professionals enhanced patient compliance and outcomes

By end user, the contract research & manufacturing organizations (CROs/CMOs) segment is expected to show the highest growth during the predicted time. The growing research and development of antibody therapies is increasing the use of CROs/CMOs services. Furthermore, growing clinical trials are also contributing to the same.

Regional Insights

Antibody Therapy Market Share, By Region, 2024 (%)

Advanced Healthcare Drives North America

North America dominated the antibody therapy market share by 45% in 2024. North America consisted of a well-developed healthcare sector, along with the presence of advanced technologies and skilled personnel. This enhanced the production and development of antibody therapies. Thus, this contributed to the market growth.

The U.S. Antibody Therapy Market Trends

The industries in the U.S. are well developed and are contributing to the accelerated production of antibody therapies to treat various diseases. At the same time, the use of advanced technologies is helping in their optimization and discoveries. The fundings are also enhancing their development and trials.

The Canada Antibody Therapy Market Trends

The growing use of bispecific antibodies and antibody drug conjugates is resulting in the increased use of antibody therapies in Canada. Moreover, the growing rates of cancer or autoimmune diseases are increasing their early adoption. Thus, their development and approvals are supported by various investments.

Growing Diseases Boost Asia Pacific

Asia Pacific is expected to host the fastest-growing antibody therapy market during the forecast period. The increasing incidence of various diseases in the Asia Pacific is increasing the demand for the use of antibody therapy. Their development is also supported by the investments. Thus, this enhances the market growth.

The China Antibody Therapy Market Trends

The growing investments in the healthcare sector of China are enhancing the development and production of antibody discoveries as well as antibody therapies. Moreover, new therapies are being discovered and evaluated by leveraging advanced technologies. At the same time, the aging population is increasing its use.

The India Antibody Therapy Market Trends

The increasing diseases in India is increasing the use of antibody therapies. This, in turn, is promoting their development as well as research. Therefore, there is a rise in the clinical trials as well. Furthermore, investments are also provided by the government to make them affordable and accessible.

Europe Driven by Increasing R&D

Europe is expected to grow significantly in the antibody therapy market during the forecast period. The industries and institutes in Europe are focused on developing and discovering new antibody targets and therapies. This, in turn, is increasing the candidates for clinical trials. Thus, this promotes the market growth.

The Germany Antibody Therapy Market Trends

The use of various antibody therapies in Germany is increasing to deal with the growing diseases. This, in turn, is leading to new research and development, promoting innovative therapies. Moreover, funding is provided to encourage these advancements by the government.

The UK Antibody Therapy Market Trends

The R&D sector of the industries and the institutions present in the UK are increasing the development as well as innovations in the antibody therapies. This, in turn, is increasing the number of clinical trials conducted. Additionally, new collaborations are promoting these developments. Furthermore, the use of advanced technologies is improving their design and discoveries.

Which are the Top Companies in the Antibody Therapy Market?

Antibody Therapy Market Companies

Latest Announcements by Industry Leaders

  • In June 2025, after the launch of BeiGene developed Tevimbra, an anti-PD-1 monoclonal antibody by Glenmark Pharmaceuticals Ltd in India, its president and business head of India formulations, Alok Malik, stated that, the Tevimbra is backed by strong science, meaningful impact, enhanced efficacy, and safety outcomes, and are proud to make it available to the oncologists and patients in this rising cancer burden. The difficult-to-treat cancer types are provided with various treatment approaches by immune-oncology. Thus, their foray in this area will help them to develop an inclusive, innovative, and world-class oncology portfolio, which will be life-changing for patients. They extended their acknowledgment to BeiGene and Pi Health for their studies on Tevimbra. (Source - PharmaBiz)
  • In May 2025, after the initiation of the Phase 1 study for an investigational anti-TL1A antibody developed with Absci’s generative AI platform, that is ABS-101, PhD, Absci Chief Innovation Officer, Andreas Busch, stated that they are thrilled for the Phase 1 clinical trials of ABS-101. Moreover, it shows enhanced affinity and potency, extended dosing interval, and is anticipated to show low immunogenicity, which was achieved by AI as it was designed and optimized using their generative AI platform.

What are the Recent Developments in the Antibody Therapy Market?

  • In June 2025, the protein language model, GLIMPSE-1, was launched by Infinimmune, which is a biotechnology company focusing on human-first antibody discovery and design. As it applies the design principles of the human adaptive immune system, this platform can be used to develop therapeutic antibodies. (Source - Globenewswire)
  • In March 2025, an award of $30 million was granted to the Vanderbilt University Medical Center, which will be used in artificial intelligence technologies for the development of antibody therapies.

Segments Covered in the Report

By Type of Antibody 

  • Monoclonal Antibodies (mAbs) 
    • Fully Human mAbs 
    • Humanized mAbs 
    • Chimeric mAbs 
  • Polyclonal Antibodies 
  • Bispecific Antibodies 
    • T-cell Engagers 
    • Dual Antigen Binders 
  • Antibody-Drug Conjugates (ADCs) 
  • Immune Checkpoint Inhibitors 
    • PD-1 / PD-L1 Inhibitors 
    • CTLA-4 Inhibitors 

By Therapy Area 

  • Oncology 
    • Breast Cancer 
    • Lung Cancer 
    • Hematologic Malignancies (e.g., Leukemia, Lymphoma)
  • Autoimmune Diseases
    • Rheumatoid Arthritis
    • Psoriasis
    • Inflammatory Bowel Disease (IBD)
  • Infectious Diseases
    • COVID-19
    • RSV, HIV, Hepatitis
  • Cardiovascular & Metabolic Disorders
    • PCSK9 Inhibitors for Hypercholesterolemia
  • Neurology
    • Alzheimer's Disease
    • Multiple Sclerosis 
  • Ophthalmology
    • Wet AMD (Age-related Macular Degeneration)

By Mechanism of Action

  • Targeted Cell Killing 
    • ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) 
    • CDC (Complement-Dependent Cytotoxicity) 
  • Immune Modulation 
    • Checkpoint Blockade 
    • Immune Cell Activation 
  • Neutralization 
    • Blocking Ligands or Receptors
  • Payload Delivery 
    • Antibody-Drug Conjugates 

By Route of Administration 

  • Intravenous (IV) 
  • Subcutaneous (SC) 
  • Intramuscular (IM) 
  • Intraocular (for retinal antibodies) 

By End-User 

  • Hospitals & Clinics 
  • Specialty Oncology Centers 
  • Research & Academic Institutions 
  • Contract Research & Manufacturing Organizations (CROs/CMOs)
  • Retail & Specialty Pharmacies 

By Region 

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 14 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The antibody therapy market is projected to reach USD 951.24 billion by 2034, growing at a CAGR of 13.08% from 2024 to 2034.

North America is currently leading the antibody therapy market due to the presence of the advanced healthcare sector.

The antibody therapy market includes six segments such as by type of antibody, by therapy area, by mechanism of action, by route of administration, by end-user, and by region. 

Some key players include Takeda Pharmaceuticals, Bristol-Myers Squibb, Novartis AG, and Merck & Co., Inc.

Key trends include innovation in anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy and rising bispecific antibody use for transforming cancer care.

Diseases such as cancer, autoimmune disorders, infectious diseases, and inflammatory conditions are treated with the use of antibody therapy.

Growing advancements in antibody discovery are the factor that drives the market.

American Cancer Society, Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.